NO20051908L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20051908L
NO20051908L NO20051908A NO20051908A NO20051908L NO 20051908 L NO20051908 L NO 20051908L NO 20051908 A NO20051908 A NO 20051908A NO 20051908 A NO20051908 A NO 20051908A NO 20051908 L NO20051908 L NO 20051908L
Authority
NO
Norway
Prior art keywords
alkyl
heteroaryl
aryl
carbocyclyl
heterocyclyl
Prior art date
Application number
NO20051908A
Other languages
English (en)
Inventor
Elisa Henderson
Richard Kelsey
Lara Wilson
Phil Chambers
Malcolm Carter
Debra Taylor
Stan Tyms
Original Assignee
Arrow Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0221923.6A external-priority patent/GB0221923D0/en
Priority claimed from GB0302078A external-priority patent/GB0302078D0/en
Application filed by Arrow Therapeutics Ltd filed Critical Arrow Therapeutics Ltd
Publication of NO20051908L publication Critical patent/NO20051908L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Benzodiazepinderivat med formel (I), og farmasøytisk akseptable salter derav, er funnet å være aktive mot RSV hvori: - R1 representerer C1-6 alkyl, aryl eller heteroaryl; - R2 representerer hydrogen eller C1-6 alkyl; - hver R3 er det samme eller forskjellige og representerer halogen, hydroksy, Cl-6 alkyl, Cl-6 alkoksy, Cl-6 alkyltio, Cl-6 haloalkyl, Cl-6 haloalkoksy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2R', -CONR'R'', -NH-CO-R', -S(O)R', -S(O)2R', -NH-S(O)2R', -S(O)NR'R" eller -S(O)2NR'R'', hvori hver R' og R'' er det samme eller forskjellige og representerer hydrogen eller C1-6 alkyl; - n er fra 0 til 3; - R4 representerer hydrogen eller Cl-6 alkyl; - R5 representerer Cl-6 alkyl, aryl, heteroaryl, karbocyklyl, heterocyklyl, aryl-(C1-6 alkyl)-, heteroaryl(C1-6 alkyl) -, karbocyklyl- (C1-6 alkyl) -, heterocyklyl- (C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, karbocyklyl-C(O)-C(O)-, heterocyklyl-C(O)-C(O)- eller -XR6; - X representerer -CO-, -S(O)- eller -S(0)2; og - R6 representerer Cl-6 alkyl, hydroksy, Cl-6 alkoksy, Cl-6 alkyltio, aryl, heteroaryl, karbocyklyl, heterocyklyl, aryl- (C1-6 alkyl) -, heteroaryl- (C1-6 alkyl) -, karbocyklyl- (C1-6 alkyl) -, heterocyklyl- (C1-6 alkyl) -, aryl- (C1-6 hydroksyalkyl) -, heteroaryl- (C1-6 hydroksyalkyl)-, karbocyklyl-(C1-6 hydroksyalkyl)-, heterocyklyl-(C1-6 hydroksyalkyl) -, aryl- (C1-6 alkyl)-O-, heteroaryl- (C1-6 alkyl)-O-, karbocyklyl-(C1-6 alkyl)-O-, heterocyklyl-(C1-6 alkyl)-O- eller -NR'R'' hvori hver R' og R'' er det samme eller forskjellige og representerer hydrogen, Cl-6 alkyl, karbocyklyl, heterocyklyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, karbocyklyl- (C1-6 alkyl)-, eller heterocyklyl- (C1-6 alkyl)-.
NO20051908A 2002-09-20 2005-04-19 Kjemiske forbindelser NO20051908L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0221923.6A GB0221923D0 (en) 2002-09-20 2002-09-20 Chemical compounds
GB0302078A GB0302078D0 (en) 2003-01-29 2003-01-29 Chemical compounds
PCT/GB2003/004050 WO2004026843A1 (en) 2002-09-20 2003-09-22 Benzodiazepine derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
NO20051908L true NO20051908L (no) 2005-04-19

Family

ID=32031886

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20051908A NO20051908L (no) 2002-09-20 2005-04-19 Kjemiske forbindelser
NO20140629A NO20140629L (no) 2002-09-20 2014-05-19 Kjemiske forbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20140629A NO20140629L (no) 2002-09-20 2014-05-19 Kjemiske forbindelser

Country Status (16)

Country Link
US (2) US7582624B2 (no)
EP (1) EP1539716A1 (no)
JP (2) JP4719466B2 (no)
KR (1) KR101125899B1 (no)
AU (1) AU2003267587B2 (no)
BR (1) BR0314595A (no)
CA (1) CA2499322C (no)
EA (1) EA012387B1 (no)
IL (1) IL167332A (no)
IS (1) IS7735A (no)
MX (1) MXPA05002871A (no)
NO (2) NO20051908L (no)
NZ (2) NZ538870A (no)
PL (1) PL375860A1 (no)
WO (1) WO2004026843A1 (no)
ZA (1) ZA200502001B (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
WO2005090319A1 (en) * 2004-03-19 2005-09-29 Arrow Therapeutics Limited Process for preparing benzodiazepines
GB0406280D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
BRPI0520554A2 (pt) 2005-09-19 2009-06-13 Arrow Therapeutics Ltd uso de uma benzodiazepina ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou prevenir uma infecção por hcv em um paciente, derivado de benzodiazepina ou um sal famaceuticamente aceitável do mesmo, e, composição farmacêutica
AU2007267671A1 (en) 2006-05-23 2007-12-06 Novartis Ag Salts and crystal modifications thereof
PL2094308T3 (pl) * 2006-11-21 2011-06-30 Novartis Ag Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
EA201590197A1 (ru) 2012-08-23 2015-07-30 Алиос Биофарма, Инк. Соединения для лечения парамиксовирусных вирусных инфекций
WO2014047392A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
JP2015531792A (ja) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
EP2897942B1 (en) 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
EP2981267A1 (en) 2013-04-04 2016-02-10 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
DK3324977T3 (da) * 2015-07-22 2022-10-17 Enanta Pharm Inc Benzodiazepinderivater som rsv-inhibitorer
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2018226801A1 (en) * 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
CA3080138A1 (en) * 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
GB201911944D0 (en) * 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AU2020357452B2 (en) 2019-10-04 2026-01-29 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
GB201915273D0 (en) * 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
GB201915932D0 (en) 2019-11-01 2019-12-18 Reviral Ltd Pharmaceutical compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
GB202010408D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
GB202010409D0 (en) 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
GB202102602D0 (en) 2021-02-24 2021-04-07 Reviral Ltd Pharmaceutical compounds
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024252355A1 (en) 2023-06-08 2024-12-12 Pfizer Inc. Pediatric dosing regimens comprising a fusion inhibitor for the treatment of rsv
WO2025120500A1 (en) 2023-12-06 2025-06-12 Pfizer Inc. Benzodiazepine compounds as n-protein inhibitors
WO2025153942A1 (en) 2024-01-16 2025-07-24 Pfizer Inc. Benzodiazepine pyrazolo carboxamides as n-protein inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE656606A (no) * 1963-12-03
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
CA1332410C (en) 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
FR2641280B1 (fr) 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
US4628084A (en) * 1986-01-02 1986-12-09 Merck & Co., Inc. Process for 3-acylamino benzodiazepines
CA2026856A1 (en) 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
IL96613A0 (en) 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
EP0475231A1 (en) 1990-09-10 1992-03-18 F. Hoffmann-La Roche Ag Benzodiazepines
EP0491218A1 (en) 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
US5218115A (en) 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5220018A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5220017A (en) 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
EP0523845A3 (en) 1991-06-14 1993-11-18 Merck & Co Inc New benzodiazepine analogs
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
US5428031A (en) 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
GB9203790D0 (en) * 1992-02-21 1992-04-08 Merck Sharp & Dohme Therapeutic agents
US5426185A (en) 1993-11-22 1995-06-20 Merck & Co., Inc. Antiarrhythmic benzodiazepines
FR2716195B1 (fr) 1994-02-14 1996-06-21 Sanofi Sa Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US5776930A (en) * 1996-06-28 1998-07-07 Merck & Company, Inc. Pharmaceutical preparation
WO1998000406A1 (en) 1996-07-02 1998-01-08 Merck & Co., Inc. Method for the treatment of preterm labor
KR100212435B1 (ko) 1996-09-04 1999-08-02 이서봉 1,4-벤조디아제핀-2,5-디온 유도체 및 약학적으로 허용되는 그의 염
AU4917397A (en) 1996-10-31 1998-05-22 Merck & Co., Inc. Benzodiazepine hydrazide derivatives as inhibitors of hiv integrase
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
BR9913226A (pt) 1998-09-01 2001-05-22 Innogenetics Nv Benzodiazepinas e derivados de benzotiazepinas e peptìdios de hbsag ligados a anexinas, suas composições e uso
FR2785803B1 (fr) 1998-11-17 2005-03-25 Sanofi Sa Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
JP5127096B2 (ja) 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
SI1196408T1 (en) 1999-06-28 2005-02-28 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
CN1436175A (zh) 2000-04-03 2003-08-13 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ－蛋白生产抑制剂的环状内酰胺
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
CN1179752C (zh) 2000-08-16 2004-12-15 中国医学科学院药物研究所 含咪唑丙酰胺基的苯并二氮杂�类化合物以及制法和用途
AU2002219846A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Novel use
SE0104250D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Heterocyclic compounds

Also Published As

Publication number Publication date
ZA200502001B (en) 2006-05-31
WO2004026843A1 (en) 2004-04-01
AU2003267587A1 (en) 2004-04-08
EA012387B1 (ru) 2009-10-30
KR20050051664A (ko) 2005-06-01
JP4719466B2 (ja) 2011-07-06
IL167332A (en) 2013-10-31
US8119630B2 (en) 2012-02-21
EP1539716A1 (en) 2005-06-15
NZ538870A (en) 2007-04-27
US20100015063A1 (en) 2010-01-21
CA2499322A1 (en) 2004-04-01
NO20140629L (no) 2005-04-19
NZ570344A (en) 2010-04-30
US20060040923A1 (en) 2006-02-23
CA2499322C (en) 2012-04-24
JP2006503054A (ja) 2006-01-26
PL375860A1 (en) 2005-12-12
US7582624B2 (en) 2009-09-01
MXPA05002871A (es) 2005-10-05
EA200500511A1 (ru) 2006-02-24
IS7735A (is) 2005-03-10
KR101125899B1 (ko) 2012-04-12
JP2011088907A (ja) 2011-05-06
AU2003267587B2 (en) 2010-05-20
BR0314595A (pt) 2005-08-09
JP5298103B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
NO20051908L (no) Kjemiske forbindelser
NO20073465L (no) Benzotiazol-derivater
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
JO2371B1 (en) 4-phenyl-pyridine derivatives
NO20062726L (no) Nye pyridazin-3(2H)-on derivater
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20055562L (no) Substituerte indolin- og indolderivater
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
MXPA05007671A (es) Derivados de triazina como absorbedores de uv.
EP1442016A4 (en) 1H-INDOLDERIVATE AS HIGH-DETECTIVE CYCLOOXYGENASE-2 INHIBITORS
BRPI0508968A (pt) benzodiazepinas para tratamento ou prevenção de infecção pelo rsv
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20035524D0 (no) 4'-substituerte nukleosider
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20064151L (no) Nye forbindelser
NO20054848L (no) Substituerte p-diaminobenzenderivater
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
PT1337535E (pt) Derivados de benzodiazepina
CA2401812A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
NO20081861L (no) Benzodiazepinderivater for behandling av hepatitt C-infeksjon
MY140235A (en) New benzimidazole derivatives
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
ATE316962T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application